Abstract
Human induced pluripotent stem cells (hiPSCs) have great potential as a robust source of progenitors for regenerative medicine. The novel technology also enables the derivation of patient-specific cells for applications to personalized medicine, such as for personal drug screening and toxicology. However, the biological characteristics of iPSCs are not yet fully understood and their similarity to human embryonic stem cells (hESCs) is still unresolved. Variations among iPSCs, resulting from their original tissue or cell source, and from the experimental protocols used for their derivation, significantly affect epigenetic properties and differentiation potential. Here we review the potential of iPSCs for regenerative and personalized medicine, and assess their expression pattern, epigenetic memory and differentiation capabilities in relation to their parental tissue source. We also summarize the patient-specific iPSCs that have been derived for applications in biological research and drug discovery; and review risks that must be overcome in order to use iPSC technology for clinical applications.
Keywords: Differentiation, epigenetic memory, hES cells, iPS cells, personalized medicine, regenerative medicine, reprogramming.
Current Molecular Medicine
Title:Induced Pluripotent Stem Cells (iPSCs) Derived from Different Cell Sources and their Potential for Regenerative and Personalized Medicine
Volume: 13 Issue: 5
Author(s): R. Shtrichman, I. Germanguz and J. Itskovitz- Eldor
Affiliation:
Keywords: Differentiation, epigenetic memory, hES cells, iPS cells, personalized medicine, regenerative medicine, reprogramming.
Abstract: Human induced pluripotent stem cells (hiPSCs) have great potential as a robust source of progenitors for regenerative medicine. The novel technology also enables the derivation of patient-specific cells for applications to personalized medicine, such as for personal drug screening and toxicology. However, the biological characteristics of iPSCs are not yet fully understood and their similarity to human embryonic stem cells (hESCs) is still unresolved. Variations among iPSCs, resulting from their original tissue or cell source, and from the experimental protocols used for their derivation, significantly affect epigenetic properties and differentiation potential. Here we review the potential of iPSCs for regenerative and personalized medicine, and assess their expression pattern, epigenetic memory and differentiation capabilities in relation to their parental tissue source. We also summarize the patient-specific iPSCs that have been derived for applications in biological research and drug discovery; and review risks that must be overcome in order to use iPSC technology for clinical applications.
Export Options
About this article
Cite this article as:
Shtrichman R., Germanguz I. and Eldor J. Itskovitz-, Induced Pluripotent Stem Cells (iPSCs) Derived from Different Cell Sources and their Potential for Regenerative and Personalized Medicine, Current Molecular Medicine 2013; 13 (5) . https://dx.doi.org/10.2174/1566524011313050010
DOI https://dx.doi.org/10.2174/1566524011313050010 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Beta-Blockers for the Treatment of Essential Hypertension: What are the Arguments Against Their Use as First Line Therapy?
Current Hypertension Reviews Atrial Fibrillation: The Emerging Role of Inflammation and Oxidative Stress
Cardiovascular & Hematological Disorders-Drug Targets Immunomodulatory Actions of Vitamin D Metabolites and their Potential Relevance to Human Lung Disease
Current Respiratory Medicine Reviews Genetic Variations in Cytochrome P450 2C9 and 2C19: A Review
Current Pharmacogenomics and Personalized Medicine VIP in Inflammatory Bowel Disease: State of the Art
Endocrine, Metabolic & Immune Disorders - Drug Targets Effects of Metabolic Approach in Diabetic Patients with Coronary Artery Disease
Current Pharmaceutical Design Plasminogen Activator Inhibitor-1
Current Medicinal Chemistry Liver Enzymes: Potential Cardiovascular Risk Markers?
Current Pharmaceutical Design The Clinical Utility of Ambulatory Blood Pressure Monitoring (ABPM): A Review
Current Hypertension Reviews Is there Sex-related Outcome Difference According to oral P2Y12 Inhibitors in Patients with Acute Coronary Syndromes? A Systematic Review and Meta-Analysis of 107,126 Patients
Current Vascular Pharmacology Targeting the Coagulation Factor Fibrinogen for Arthritis Therapy
Current Pharmaceutical Biotechnology Atorvastatin Inhibits Advanced Glycation End Products (AGE)-Induced C-Reactive Expression in Hepatoma Cells by Suppressing Reactive Oxygen Species Generation
Vascular Disease Prevention (Discontinued) Effect of Chronic Melatonin Administration on Several Physiological Parameters from Old Wistar Rats and Samp8 Mice
Current Aging Science Angiotensin Converting Enzyme 2 Activator (DIZE) Modulates Metabolic Profiles in Mice, Decreasing Lipogenesis
Protein & Peptide Letters Treatment Considerations of Clinical Physician on Hypertension Management in Asia
Current Hypertension Reviews Targets for Anti-T. cruzi Drugs in the Post-Genomic Era
Current Enzyme Inhibition Interventions Against Sarcopenia in Older Persons
Current Pharmaceutical Design A Role for Rev-erbα Ligands in the Regulation of Adipogenesis
Current Pharmaceutical Design Persistent Pulmonary Hypertension of the Newborn: Physiology, Hemodynamic Assessment and Novel Therapies
Current Pediatric Reviews MicroRNA Regulation and Role in Stem Cell Maintenance, Cardiac Differentiation and Hypertrophy
Current Molecular Medicine